NCT00265395View on ClinicalTrials.gov

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,428

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)

"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"

DRUG

Combination of pegylated interferon alfa-2b and ribavirin

"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00265395 - Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) | Biotech Hunter | Biotech Hunter